Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 232.68 +8.15 (3.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $224.53 | 52 Week High | $109.10 | |||
| Open | $224.74 | 52 Week Low | $31.38 | |||
| Day High | $232.94 | P/E | N/A | |||
| Day Low | $222.71 | EPS | $-1.45 | |||
| Volume | 959,452 | |||||
